- Sedentary time decreased, stepping time increased, and number of steps per day increased among patients with chronic kidney disease assigned to the 'Sit Less, Interact, Move More' intervention.
- These effects were not sustained after 20 weeks, however.
Washington, DC (April 22, 2021) -- A recent randomized trial tested an intervention to reduce sedentary time and increase physical activity in individuals with kidney disease. The findings will appear in an upcoming issue of CJASN.
Sedentary behavior is very common in individuals with chronic kidney disease (CKD), especially those with more advanced stages, and it's linked with a higher risk of dying prematurely.
A team led by Srinivasan Beddhu, MD (University of Utah School of Medicine and Veterans Affairs Salt Lake City Health Care System) and Kate Lyden, PhD (University of Massachusetts, Amherst and Colorado State University) designed a study to see whether light intensity casual stepping could decrease sedentary time to improve health and well-being in patients with moderate-to-advanced CKD.
In this single center, pilot, open-labeled, randomized controlled trial conducted at the University of Utah, participants' activity was assessed through accelerometers attached the skin on the midline of the thigh. The 54 patients assigned to the 'Sit Less, Interact, Move More' intervention received educational materials, were shown graphic displays of their accelerometer summaries, and were provided feedback on when they were most sedentary. They were instructed to get up from sitting/lying posture while awake at least once per hour and to engage in light intensity activities. The 52 participants in the control group were provided national physical activity recommendations.
The researchers found that by week 20, sedentary time decreased by an average of 43 minutes per day, stepping time increased by 16 minutes per day, and number of steps per day increased by 1, 265 in the intervention group. Although the intervention reduced the amount of time that patients were sedentary and increased the amount of time that they walked, these effects were not sustained over subsequent weeks.
"These results suggest that while it is feasible to reduce sedentary duration in patients with CKD, additional co-interventions might be needed to sustain these effects long-term," said Dr. Beddhu.
Dr. Beddhu stressed that physical inactivity (not achieving the weekly moderate/vigorous activities goal of 150 minutes/week) is distinct from sedentary behavior (sitting/lying down most of the time). "One can be physically active and reach the weekly goal of 150 minutes per week--2% of awake time--but still be sedentary by sitting or lying down for the reminder of the 98% awake time. Hence, it is important to address both physical inactivity and sedentary behavior for a healthier lifestyle," he said.
An accompanying editorial noted that kidney specialists are uniquely positioned to assist individuals who are sedentary and living with CKD to make meaningful lifestyle changes that will improve their overall health and quality of life. "The kidney health community would benefit from future pragmatic clinical trials of a multidisciplinary approach to improving health and wellness in populations living with CKD," wrote author Baback Roshanravan, MD, MS, MSPH (University of California Davis).
Study co-authors include Robert Boucher, BS, Guo Wei, MS, Na Zhou, MD, Jesse Christensen, DPT, PhD, Glenn M. Chertow, MD, MPH, and Tom Greene, PhD.
Disclosures: This study was funded by a grant from the National Institutes of Health. S. Beddhu reports employment with University of Utah School of Medicine; consultancy agreements with Bayer and Reata; receiving research funding from Bayer, Boehringer-Ingelheim, and Novartis; and serving as a scientific advisor or member of CJASN and Kidney Reports. R. Boucher reports employment with University of Utah School of Medicine. G.M. Chertow reports employment with Stanford University School of Medicine; consultancy agreements with Akebia, Amgen, Ardelyx, AstraZeneca, Baxter, Cricket, DiaMedica, Gilead, Miromatrix, Reata, Sanifit, and Vertex; ownership interest in Ardelyx, CloudCath, Durect, DxNow, Eliaz Therapeutics, Outset, Physiowave, and PuraCath; receiving research funding from NIDDK and NIAID; serving on the Board of Directors of Satellite Healthcare and as coeditor of Brenner & Rector's The Kidney (Elsevier); and DSMB service for Angion, Bayer, NIDDK, and ReCor. J. Christensen and G. Wei report employment with University of Utah. T. Greene reports employment with University of Utah; consultancy agreements with AstraZeneca, Invokana, Janssen Pharmaceuticals, Novartis, and Pfizer Inc.; and receiving research funding from AstraZeneca, Boehringer-Ingleheim, CSL, and Vertex. K. Lyden reports employment with KAL Research/Consulting and VivoSense, Inc and ownership interest in VivoSense, Inc.
The article, titled "Targeting Sedentary Behavior in Chronic Kidney Disease: A Pilot and Feasibility Randomized Controlled Trial," will appear online at http://cjasn.
The editorial, titled "Moving Beyond Sedentarism in CKD," will appear online at http://cjasn.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 21,000 members representing 131 countries. For more information, visit http://www.